The promise of stem cell research, once deemed a scientists' dream, has turned the corner into real marketed products and looks to soon be a multi-billion-dollar industry. Randal Mills, the chief executive officer of Osiris Therapeutics tells the Chicago Tribune's Bruce Japsen about stem cell products already on the market and how more are soon coming to physicians and their patients.
The Promise of Stem Cells Reaching Patients
Share this program on:
Choose a format
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Details
Presenters
Recommended
Details
Presenters
Overview
The promise of stem cell research, once deemed a scientists' dream, has turned the corner into real marketed products and looks to soon be a multi-billion-dollar industry. Randal Mills, the chief executive officer of Osiris Therapeutics tells the Chicago Tribune's Bruce Japsen about stem cell products already on the market and how more are soon coming to physicians and their patients.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
Cardiology
Phase 3 study results of plozasiran in patients with FCS
<p>Phase 3 study results of plozasiran in patients with FCS</p>
CME/CE
FCS and SHTG: Are We Meeting the Need?
0.25 credits
<p>FCS and SHTG: Are We Meeting the Need?</p>
CME/CE Broadcast Replay
Love Story: Lipid Education for Women’s Heart Health
0.50 credits
<p>Love Story: Lipid Education for Women’s Heart Health</p>
MinuteCE®
HF Management for Patients with Comorbid Conditions
0.75 credits
<p>HF Management for Patients with Comorbid Conditions</p>
MinuteCE®
Level Up Your Skills: Tailoring Management of HF
0.75 credits
<p>Level Up Your Skills: Tailoring Management of HF</p>
NeuroFrontiers
Rozanolixizumab for Myasthenia Gravis: An Alternative to Corticosteroids
<p>Rozanolixizumab for Myasthenia Gravis: An Alternative to Corticosteroids</p>
Cardiology
Analysis of Patients With and Without AF Living With HFmrEF/HFpEF: FINEARTS-HF
<p>Analysis of Patients With and Without AF Living With HFmrEF/HFpEF: FINEARTS-HF</p>
Cardiology
Effect of Finerenone on NT-proBNP in HFmrEF/HFpEF: FINEARTS-HF Trial
<p>Effect of Finerenone on NT-proBNP in HFmrEF/HFpEF: FINEARTS-HF Trial </p>
Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?